Why the study?
There is a lack of available therapeutic options targeting Kv7.2/7.3 channels for brain hyperexcitability disorders after the clinical withdrawal of retigabine in late 2016.
Design
Review
Authors
Loading...
Summarizes computational strategies for Kv7.2/7.3 agonist design; leaves open clinical translation in epileptic encephalopathies pending validation.
This review summarizes computational approaches for discovering novel Kv7.2/7.3 channel agonists, which are needed for treating epileptic encephalopathies following the withdrawal of retigabine.
Stagno et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: